8-K
BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates
8-K
BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia
8-K
BridgeBio Enters Voluntary Agreement with U.S. Government to Expand Medicaid Access and Lower Drug Costs
8-K
BridgeBio Pharma Announces Secondary Offering of 5,000,000 Shares by KKR Genetic Disorder L.P.
8-K
BridgeBio Reports Second Quarter 2026 Financial Results and Pipeline Progress
8-K
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
